Ahead of FDA, EMA gives thumbs-up to AstraZeneca, Sanofi's RSV antibody for infants and newborns
The partnership between AstraZeneca and Sanofi paid off on Friday.
The two European Big Pharmas put out word that their jointly-developed antibody Beyfortus (nirsevimab) was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
